-+ 0.00%
-+ 0.00%
-+ 0.00%

Citigroup Maintains Buy on CRISPR Therapeutics, Raises Price Target to $88

Benzinga·08/04/2026 15:24:40
Listen to the news
Citigroup analyst Yigal Nochomovitz maintains CRISPR Therapeutics (NASDAQ:CRSP) with a Buy and raises the price target from $82 to $88.